Charcot-Marie-Tooth and Other Hereditary Motor and Sensory Neuropathies 

  • Author: Timothy C Parsons, MD; Chief Editor: Nicholas Lorenzo, MD   more...
 
Updated: Apr 25, 2011
 

Background

Slowly progressive distal weakness, muscle atrophy, and sensory loss due to an inherited peripheral neuropathy was described independently in 1886 by Charcot and Marie in France and by Tooth in England.[1, 2] A few years later, Dejerine and Sottas recognized and described a more severe, infantile form of inherited neuropathy.[3]

As more heterogeneity and overlap in clinical appearance, pathological features, and forms of inheritance were recognized in the following decades, an improved classification system was needed to avoid confusion. Starting in the 1950s, the clinical use of nerve conduction studies combined with pathological information allowed patients to be divided into 2 major groups.

  • Group 1 was characterized by slow nerve conduction velocities and evidence of hypertrophic demyelinating neuropathy.
  • Group 2 was characterized by relatively normal nerve conduction velocities and axonal degeneration.

Most of the families demonstrated autosomal dominant inheritance, and affected relatives in each family could all be categorized in the same group.[4, 5, 6]

In 1975, Dyck expanded the classification system of what was now known as hereditary motor and sensory neuropathy (HMSN) to include forms with additional features.[7]

  • HMSN types 1A and 1B (dominantly inherited hypertrophic demyelinating neuropathies)
  • HMSN type 2 (dominantly inherited neuronal neuropathies)
  • HMSN type 3 (hypertrophic neuropathy of infancy [Dejerine-Sottas])
  • HMSN type 4 (hypertrophic neuropathy [Refsum] associated with phytanic acid excess)
  • HMSN type 5 (associated with spastic paraplegia)
  • HMSN type 6 (with optic atrophy)
  • HMSN type 7 (with retinitis pigmentosa)

In the 1980s it became clear that this revised classification system, based on clinical and electrophysiologic characteristics, was inadequate to describe the genetic heterogeneity within each of these categories. Linkage studies revealed Charcot-Marie-Tooth type 1 loci on both chromosome 1[8] and chromosome 17[9] , and X-linked and recessively inherited forms were increasingly recognized.

In 1991, 2 groups showed that the most common form of CMT1, known as CMT1A, was associated with a duplication within chromosome 17p11.2.[10, 11] This duplication is believed to be in the peripheral myelin protein 22kD (PMP22) gene, and overexpression of the gene product appears to be causative, since a gene dosage effect has been demonstrated.[12] It is estimated that this duplication is responsible for about 70% of CMT1 cases[13] and the vast majority of CMT1A cases, with rare exceptions such as partial 17p trisomy.[12, 14]

Other Charcot-Marie-Tooth genes were discovered in the 1990s. The second most common form of CMT1 (CMT1B) and some cases of Déjerine-Sottas syndrome were found to be associated with mutations in the myelin protein zero (MPZ) gene on chromosome 1.[15, 16, 17] The most common form of CMTX (CMTX1), was found to be due to mutations in the gap junction protein beta 1/connexin 32 (Cx32) on chromosome Xq13.1.[18] Interestingly, hereditary neuropathy with liability to pressure palsies (HNPP) was found to be associated with a deletion in the PMP22 gene[19] , but this syndrome will not be reviewed here.

The difficulty classifying Charcot-Marie-Tooth subtypes is made more evident by the fact that mutations of each of these genes have been associated with multiple, overlapping phenotypes. For instance, myelin protein zero mutations are associated CMT1B, Déjerine-Sottas syndrome, and the axonal CMT2 phenotype.[20, 21] Déjerine-Sottas syndrome has been associated with mutations or deletions in PMP22, myelin protein zero, and early growth response 2 (EGR2) genes.[15, 22, 23]

In addition, the boundaries between even the major types of CMT are not always as clear as the original series suggested. In the mid 1970s, Bradley, Davis, and Madrid performed a similar study to those performed by Dyck and Lambert, Thomas and Calne, and Buchthal and Behse, and proposed a CMT classification that included an intermediate group characterized by median motor nerve conduction velocities of 25-45 m/sec and intermediate pathological changes.[24, 25, 26] A study performed by Brust, Lovelace, and Devi suggested a bimodality in nerve conduction velocities among type 1 patients, again raising the possibility of an intermediate form[27] , but these were considered exceptions and were never incorporated into the major classification systems. In 1985, a large kinship with an intermediate form was described.

In 1998, sequencing of the PMP22 and MPZ genes in this kinship did not reveal mutations, underscoring that it is a distinct entity.[28, 29] Several associated mutations have been discovered since, and as with other forms of CMT, these studies have demonstrated genetic heterogeneity.

Given what is now known about clinical and genetic heterogeneity, a system that takes both clinical and genetic characteristics into account is not possible. This review will use the following system:

  • CMT1 is a dominantly inherited, hypertrophic, predominantly demyelinating form.
  • CMT2 is a dominantly inherited predominantly axonal form.
  • Dejerine-Sottas is a severe form with onset in infancy.
  • CMTX is inherited in an X-linked manner.
  • CMT4 includes the various demyelinating autosomal recessive forms of Charcot-Marie-Tooth disease.
Next

Pathophysiology

CMT1A

The extra PMP22 gene copy within the 1.5 mB duplication on chromosome 17 is believed to cause most cases.[12]PMP22 is a 160 amino acid integral membrane protein that is expressed at high levels in myelinating Schwann cells, localizing to compact myelin and making up 2–5% of total myelin protein.[30, 31]PMP22 expression in CMT1A nerve biopsies is increased[32] , but the process by which protein overexpression actually causes the Charcot-Marie-Tooth phenotype remains unclear.

Abnormal expression of PMP22 seems to alter Schwann cell growth and differentiation both in vivo and in vitro, and may impair the ability of the Schwann cell to maintain normal myelin stability and turnover. A putative interaction between PMP22 and MPZ could play a role in maintaining myelin compaction and stability, and an imbalance in one could explain why changes in expression in either gene can lead to the clinically and pathologically indistinguishable CMT1A and CMT1B phenotypes.[33]

Despite the evidence of demyelination found on pathological and electrophysiological studies and the more recent implication of myelin proteins, the signs and symptoms of weakness and sensory loss are likely the result of axonal degeneration rather than demyelination. Anatomical evidence of progressive length-dependent axonal loss following demyelination in CMT1 exists.[34] Children with CMT1A have slow nerve conduction velocities in the first years of life, generally preceding the development of signs and symptoms.[35] Krajewski and colleagues demonstrated that compound motor action potential amplitudes correlate best with weakness in CMT1A rather than nerve conduction velocities.[36]

In vivo studies of CMT1A patients have demonstrated altered axonal excitability, in the form of elevated stimulation thresholds and a markedly abnormal threshold electrotonus. These findings suggested that demyelination causes exposure of fast K+ channels, which are normally sequestered under the myelin.[37]

CMT1B

Myelin protein zero is an integral type I membrane protein, and is the most abundant structural protein of compact peripheral nerve myelin.[38, 15]

More than 80 mutations in myelin protein zero have been described. Most are associated with the typical CMT1B phenotype, but correlations have been found with other clinical phenotypes including CMT2, Dejerine Sottas syndrome, and congenital hypomyelination neuropathy.[39, 40]

Predominantly axonal and predominantly demyelinating forms appear to be due to different mutations in the same gene. Mutations that introduce a charged amino acid, removed or added a cysteine residue, or altered an evolutionarily conserved amino acid alter the tertiary structure of the MPZ protein as a result and lead to the more severe early onset phenotype. As with diseases of PMP22 expression, the mechanism for either demyelinating or axonal forms remains unclear, but may be due to impaired myelin-axon interaction.[41, 42, 43]

CMTX

CMTX is caused by mutations in connexin32/Gap Junction Beta 1 (Cx32 or GJB1), which maps to chromosome Xq13. Connexins assemble to form intercellular gap junctions, which allow the diffusion of ions and small molecules across apposed cell membranes. Connexin 32 is expressed in many tissues, but is localized in the myelin sheath of large diameter fibers near the nodes of Ranvier.[18, 44]

Axonal and demyelinating changes are mixed in CMTX. Men are clinically and electrophysiologically more severely affected than affected women. Interestingly, nerve conduction velocities in affected women can vary markedly within the same limb, in contrast to men whose conduction velocities tend to resemble the diffusely slow velocities seen in CMT1. This may be partly explained by X-inactivation of Schwann cell precursors during development. The mechanisms by which different Cx32 mutations cause CMT1X are not fully understood. Phenotype-genotype correlations in CMT1X will be difficult to establish because of phenotypic variability both within and between kindreds.[45, 46, 47]

CMT2

The most common mutation responsible for CMT2 has been found in the mitochondrial GTPase mitofusin 2 (MFN2) gene.[48] This is referred to as CMT2A.

MFN2 is a dynamin family GTPase that spans the outer mitochondrial membrane and is believed to primarily be involved in mitochondrial docking, tethering, and fusion. Recent data were supportive of a mitochondrial trafficking insult as a possible mechanism of length-dependent axonal neuropathy.[49, 50]

CMT4

The causes of CMT4 are diverse and very rare and will not be reviewed here.

Previous
Next

Epidemiology

Frequency

International

CMT is the most common inherited neuromuscular disorder. Estimates of the frequency of Charcot-Marie-Tooth disease vary widely. In 1974, Skre and colleagues reported a prevalence of 1 case per 2,500 individuals. A worldwide meta-analysis estimated a prevalence of 1 per 10,000 individuals, and a prevalence of 10.8 per 100,000 was found in western Japan.[51, 52]

Charcot-Marie-Tooth disease type 1 accounts for about two thirds of CMT cases. Of these, 70% are due to duplications in PMP22. Duplications in PMP22 therefore account for roughly half of all combined CMT subtypes.[13, 53] CMT1B makes up about 5% of CMT1 and about 1.6% of all CMT cases.[53, 54]

Charcot-Marie-Tooth disease type 2 accounts for about 22% of CMT cases.[53] CMT2A (MFN2 mutation) has been estimated to account for 11-23% of all CMT2 cases.[55]

Charcot-Marie-Tooth disease type X accounts for about 16% of CMT cases.[53] CMTX1 (Cx32 mutation) accounts for most CMTX cases and may be the second most common cause of CMT overall, at 7-20%.[41, 42]

Mortality/Morbidity

Most people with CMT have a normal life expectancy, the exceptions being patients with respiratory involvement or severe disability. Disability varies greatly both between and within families, and can range from asymptomatic with minimal examination findings to severe. Marked differences in clinical severity have even been reported in monozygotic twins with CMT1A (despite similar nerve conduction velocities)[56] and myelin protein zero mutations[57] .

A 2001 study showed that 44% of CMT1A patients were significantly disabled, and 18% were depressed. It was estimated that CMT1 patients suffer emotional stress similar to patients with stroke and comparable disability.[58]

CMT is nearly always slowly progressive. A longitudinal study showed steady progression in nerve conduction velocity and disability, and severity could be predicted based on nerve conduction velocity abnormalities in childhood.[59] Killian and colleagues studied nerve conduction velocities and neurologic examinations in 8 members of a single family over 22 years and found minimal progression of disability.[60] Another study of 43 patients with CMT2 over 5 years documented slow progression of weakness and disability, and most patients remained ambulatory.[61]

As CMT is relatively common, it can occur with other inherited or acquired neuromuscular conditions. If progression accelerates, these possibilities should be pursued.[62]

Race

No racial predilection is recognized in the common forms of CMT. Rare, recessively inherited forms (CMT4) cluster in particular ethnic groups.

Sex

As expected, CMTX affects males earlier, more frequently, and more severely than females. Other forms of CMT do not show predilection for either sex.

Age

Onset is usually in childhood. Thomas and colleagues found that 75% of patients with CMT1A developed clinical evidence of disease before age 10, and 85% before age 20.[63] Some patients experience very slow progression of mild, lifelong symptoms, and may seek medical attention only late in life.

There are patients and families in which CMT has a late onset, as late as the fifth or sixth decade in some MPZ mutations, and even as late as the seventh decade in CMT2.[40, 64]

Previous
Proceed to Clinical Presentation
 
 
Contributor Information and Disclosures
Author

Timothy C Parsons, MD  Fellow in EMG and Neuromuscular Disease, Department of Neurology, Columbia University Medical Center, New York

Timothy C Parsons, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Coauthor(s)

Thomas H Brannagan III, MD  Associate Professor of Clinical Neurology and Director, Peripheral Neuropathy Center, Columbia University, College of Physicians and Surgeons; Co-Director, EMG Laboratory, New York-Presbyterian Hospital, Columbia Campus, New York

Thomas H Brannagan III, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Peripheral Nerve Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Dianna Quan, MD  Associate Professor of Neurology, Director, Electromyography Laboratory, University of Colorado School of Medicine

Dianna Quan, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: e-medicine Honoraria Other

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Neil A Busis, MD  Chief, Division of Neurology, Department of Medicine, Head, Clinical Neurophysiology Laboratory, University of Pittsburgh Medical Center-Shadyside

Neil A Busis, MD is a member of the following medical societies: American Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Chief Editor

Nicholas Lorenzo, MD  Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants

Nicholas Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, and American College of Physician Executives

Disclosure: Nothing to disclose.

References

  1. Charcot JM. Sur une forme particulaire d'atrophie musculaire progressive souvent familial debutant par les pieds et les jambes et atteingnant plus tard les mains. Rev Med. 1886;6:97-138.

  2. Tooth HH. The peroneal type of progressive muscular atrophy. London: Lewis. 1886.

  3. Dejerine H, Sottas J. Sur la nevrite interstitielle, hypertrophique et progressive de l'enfance. CR Soc Biol (Paris). 1893;45:63-96.

  4. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol. Jun 1968;18(6):603-18. [Medline].

  5. Thomas PK, Calne DB. Motor nerve conduction velocity in peroneal muscular atrophy: evidence for genetic heterogeneity. J Neurol Neurosurg Psychiatry. Jan 1974;37(1):68-75. [Medline].

  6. Buchthal F, Behse F. Peroneal muscular atrophy (PMA) and related disorders. I. Clinical manifestations as related to biopsy findings, nerve conduction and electromyography. Brain. Mar 1977;100 Pt 1:41-66. [Medline].

  7. Dyck PJ. Inherited neuronal degeneration and atrophy affecting peripheral motor, sensory and autonomic neurons. In: Dyck PJ, Thomas PK, and Lambert EH. Peripheral Neuropathy. 2. 1. Philadelphia: Saunders; 1975:825-867.

  8. Bird TD, Ott J, Giblett ER. Evidence for linkage of Charcot-Marie-Tooth neuropathy to the Duffy locus on chromosome 1. Am J Hum Genet. May 1982;34(3):388-94. [Medline].

  9. Vance JM, Nicholson GA, Yamaoka LH, Stajich J, Stewart CS, Speer MC, et al. Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol. May 1989;104(2):186-9. [Medline].

  10. Lupski JR, de Oca-Luna RM, Slaugenhaupt S. DNA duplication associated with Charcot-Marie-Tooth Disease Type 1A. Cell. 1991;66:219-32.

  11. Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT1a). Neuromuscul Disord. 1991;1:93-7.

  12. Lupski JR, Wise CA, Kuwano A, Pentao L, Parke JT, Glaze DG. Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A. Nat Genet. Apr 1992;1(1):29-33. [Medline].

  13. Wise CA, Garcia CA, Davis SN, Heju Z, Pentao L, Patel PI. Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication. Am J Hum Genet. Oct 1993;53(4):853-63. [Medline].

  14. Fernandez-Torre JL, Otero B, Alvarez V, Hernando I, Fernandez-Toral J. De novo partial duplication of 17p associated with Charcot-Marie-Tooth disease type 1A. J Neurol Neurosurg Psychiatry. 2001;70:703-4.

  15. Hayasaka K, Himoro M, Sato W, et al. CMT neuropathy 1B is associated with mutations of the myelin P0 gene. Nat Genet. 1993;5:31-4.

  16. Kulkens T, Bolhuis PA, Wolterman RA, Kemp S, te Nijenhuis S, Valentijn LJ. Deletion of the serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-Marie-Tooth disease type 1B. Nat Genet. Sep 1993;5(1):35-9. [Medline].

  17. Su Y, Brooks DG, Li L, Lepercq J, Trofatter JA, Ravetch JV, et al. Myelin protein zero gene mutated in Charcot-Marie-tooth type 1B patients. Proc Natl Acad Sci U S A. Nov 15 1993;90(22):10856-60. [Medline].

  18. Bergoffen J, Scherer SS, Wang S, Scott MO, Bone LJ, Paul DL. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science. Dec 24 1993;262(5142):2039-42. [Medline].

  19. Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell. Jan 15 1993;72(1):143-51. [Medline].

  20. Warner LE, Hilz MJ, Appel SH, et al. Clinical phenotypes of different MPZ (P-O) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron. 1996;17:451-60.

  21. Marrosu MG, Vaccargiu S, Marrosu G, Vannelli A, Cianchetti C, Muntoni F. Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene. Neurology. May 1998;50(5):1397-401. [Medline].

  22. Numakura C, Shirahata E, Yamashita S, et al. Screening of the early growth response 2 gene in Japanese patients with Charcot-Marie-Tooth disease type 1. J Neurol Sci. 2003;210:61- 64.

  23. Roa BB, Dyck PJ, Marks HG, Chance PF, Lupski JR. Dejerine -Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (PMP22) gene. Nat Genet. 1993;5:269- 73.

  24. Bradley WG, Madrid R, and Davis, CJF . The peroneal muscular atrophy syndrome. Clinical, genetic, electrophysiological, and nerve biopsy studies. III. Clinical, electrophysiological, and pathological correlations. J Neurol Sci. 1977;32:123-36.

  25. Madrid R, Bradley WG, and Davis, CJF. The peroneal muscular atrophy syndrome. Clinical, genetic, electrophysiological, and nerve biopsy studies. II. Observations on pathological changes in sural nerve biopsies. J Neurol Sci. 1977;32:91-122.

  26. Davis CJ, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J Genet Hum. Dec 1978;26(4):311-49. [Medline].

  27. Brust JCM, Lovelace RE, and Devi S. Clinical and electrodiagnostic features of Charcot-Marie-Tooth syndrome. Acta Neurologica Scandinavica. 1978;58:Supplement 68: 1-42.

  28. Rossi A, Paradiso C, Cioni R, Rizzuto N, Guazzi G. Charcot-Marie-Tooth disease: study of a large kinship with an intermediate form. J Neurol. 1985;232(2):91-8. [Medline].

  29. Villanova M, Timmerman V, De Jonghe P, Malandrini A, Rizzuto N, Van Broeckhoven C, et al. Charcot-Marie-Tooth disease: an intermediate form. Neuromuscul Disord. Aug 1998;8(6):392-3. [Medline].

  30. Hai M, Bidichandani SI, Patel PI. Identification of a positive regulatory element in the myelin-specific promoter of the PMP22 gene. J Neurosci Res. Sep 15 2001;65(6):508-19. [Medline].

  31. Snipes GJ, Suter U, Welcher A, Shooter E. Characterization of a Novel Peripheral Nervous System Myelin Protein (PMP22/SR13). J Cell Bio. 1992;117:225-238.

  32. Vallat JM, Sindou P, Preux PM, Tabaraud F, Milor AM, Couratier P. Ultrastructural PMP22 expression in inherited demyelinating neuropathies. Ann Neurol. Jun 1996;39(6):813-7. [Medline].

  33. Müller HW. New vistas on the pathomechanism of Charcot-Marie-Tooth and related peripheral neuropathies. Ann N Y Acad Sci. Sep 14 1999;883:152-9. [Medline].

  34. Gabreëls-Festen AA, Joosten EM, Gabreëls FJ, Jennekens FG, Janssen-van Kempen TW. Early morphological features in dominantly inherited demyelinating motor and sensory neuropathy (HMSN type I). J Neurol Sci. Feb 1992;107(2):145-54. [Medline].

  35. García A, Combarros O, Calleja J, Berciano J. Charcot-Marie-Tooth disease type 1A with 17p duplication in infancy and early childhood: a longitudinal clinical and electrophysiologic study. Neurology. Apr 1998;50(4):1061-7. [Medline].

  36. Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain. Jul 2000;123 ( Pt 7):1516-27. [Medline].

  37. Nodera H, Bostock H, Kuwabara S, Sakamoto T, Asanuma K, Jia-Ying S, et al. Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain. Jan 2004;127:203-11. [Medline].

  38. Giese KP, Martini R, et al. Mouse PO Gene Disruption Leads to Hypomyelination, Abnormal Expression of Recognition Molecules, and Degeneration of Myelin and Axons. Cell. 1991;71:565-576.

  39. Nelis E, Haites N, Van Broeckhoven C. Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies. Hum Mutat. 1999;13(1):11-28. [Medline].

  40. Shy ME, Jáni A, Krajewski K, Grandis M, Lewis RA, Li J. Phenotypic clustering in MPZ mutations. Brain. Feb 2004;127(Pt 2):371-84. [Medline].

  41. Boerkoel CF, Takashima H, Garcia CA, Olney RK, Johnson J, Berry K. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol. Feb 2002;51(2):190-201. [Medline].

  42. Hattori N, Yamamoto M, Yoshihara T, Koike H, Nakagawa M, Yoshikawa H. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain. Jan 2003;126(Pt 1):134-51. [Medline].

  43. Shy ME. Peripheral neuropathies caused by mutations in the myelin protein zero. J Neurol Sci. Mar 15 2006;242(1-2):55-66. [Medline].

  44. Bruzzone R, White TW, Paul DL. Connections with connexins: the molecular basis of direct intercellular signaling. Eur J Biochem. May 15 1996;238(1):1-27. [Medline].

  45. Birouk N, Le Guern E, Maisonobe T, et al. X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiological study. Neurology. 1998;50:1074-82.

  46. Hahn AF, Bolton CF, White CM, Brown WF, Tuuha SE, Tan CC. Genotype/phenotype correlations in X-linked dominant Charcot-Marie-Tooth disease. Ann N Y Acad Sci. Sep 14 1999;883:366-82. [Medline].

  47. Dubourg O, Tardieu S, Birouk N, Gouider R, Léger JM, Maisonobe T. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease. Brain. Oct 2001;124(Pt 10):1958-67. [Medline].

  48. Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. May 2004;36(5):449-51. [Medline].

  49. Koshiba T, Detmer SA, Kaiser JT, Chen H, McCaffery JM, Chan DC. Structural basis of mitochondrial tethering by mitofusin complexes. Science. Aug 6 2004;305(5685):858-62. [Medline].

  50. Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci. Jan 10 2007;27(2):422-30. [Medline].

  51. Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord. 1991;1(1):19-29. [Medline].

  52. Kurihara S, Adachi Y, Wada K, Awaki E, Harada H, Nakashima K. An epidemiological genetic study of Charcot-Marie-Tooth disease in Western Japan. Neuroepidemiology. Sep-Oct 2002;21(5):246-50. [Medline].

  53. Ionasescu V, Searby C, Sheffield VC, Roklina T, Nishimura D, Ionasescu R. Autosomal dominant Charcot-Marie-Tooth axonal neuropathy mapped on chromosome 7p (CMT2D). Hum Mol Genet. Sep 1996;5(9):1373-5. [Medline].

  54. Nelis E, Van Broeckhoven C, De Jonghe P, Löfgren A, Vandenberghe A, Latour P. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet. 1996;4(1):25-33. [Medline].

  55. Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology. Jul 26 2005;65(2):197-204. [Medline].

  56. Garcia CA, Malamut RE, England JD, Parry GS, Liu P, Lupski JR. Clinical variability in two pairs of identical twins with the Charcot-Marie-Tooth disease type 1A duplication. Neurology. Nov 1995;45(11):2090-3. [Medline].

  57. Marques W Jr, Hanna MG, Marques SR, Sweeney MG, Thomas PK, Wood NW. Phenotypic variation of a new P0 mutation in genetically identical twins. J Neurol. Jul 1999;246(7):596-9. [Medline].

  58. Pfeiffer G, Wicklein EM, Ratusinski T, Schmitt L, Kunze K. Disability and quality of life in Charcot-Marie-Tooth disease type 1. J Neurol Neurosurg Psychiatry. Apr 2001;70(4):548-50. [Medline].

  59. Dyck PJ, Karnes JL, Lambert EH. Longitudinal study of neuropathic deficits and nerve conduction abnormalities in hereditary motor and sensory neuropathy type 1. Neurology. Oct 1989;39(10):1302-8. [Medline].

  60. Killian JM, Tiwari PS, Jacobson S, Jackson RD, Lupski JR. Longitudinal studies of the duplication form of Charcot-Marie-Tooth polyneuropathy. Muscle Nerve. Jan 1996;19(1):74-8. [Medline].

  61. Teunissen LL, Notermans NC, Franssen H, Van Engelen BG, Baas F, Wokke JH. Disease course of Charcot-Marie-Tooth disease type 2: a 5-year follow-up study. Arch Neurol. Jun 2003;60(6):823-8. [Medline].

  62. Thomas FP, Geller TJ, Hahn AF, et al. Modification of CMT1A phenotypes by independent co-existing neurogenetic disorders, McArdle disease and chromosome 5p trisomy. Ann NY Acad Sci. 1999;883:472-6.

  63. Thomas PK, Marques W Jr, Davis MB, Sweeney MG, King RH, Bradley JL, et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain. Mar 1997;120 ( Pt 3):465-78. [Medline].

  64. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain. Jun 1980;103(2):259-80. [Medline].

  65. Harding AE, Thomas PK. Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet. Oct 1980;17(5):329-36. [Medline].

  66. Rosen SA, Wang H, Cornblath DR, Uematsu S, Hurko O. Compression syndromes due to hypertrophic nerve roots in hereditary motor sensory neuropathy type I. Neurology. Sep 1989;39(9):1173-7. [Medline].

  67. Bienfait HM, Baas F, Koelman JH, de Haan RJ, van Engelen BG, Gabreëls-Festen AA. Phenotype of Charcot-Marie-Tooth disease Type 2. Neurology. May 15 2007;68(20):1658-67. [Medline].

  68. Hoogendijk J. E., Hensels G. W., Gabrëels-Festen A. A., et al. De novo mutation in hereditary motor and sensory neuropathy type 1. Lancet. 1992;339:1081-2.

  69. Berciano J, Garcia A, and Combarros O. Initial semiology in children with Charcot-Marie-Tooth disease 1A duplication. Muscle Nerve. 2003;27:34-39.

  70. Bienfait HM, Verhamme C, van Schaik IN, et al. Comparison of CMT1A and CMT2: similarities and differences. J Neurology. 2006;253:1572-80.

  71. Elliott JL, Kwon JM, Goodfellow PJ, Yee WC. Hereditary motor and sensory neuropathy IIB: clinical and electrodiagnostic characteristics. Neurology. Jan 1997;48(1):23-8. [Medline].

  72. Dyck PJ, Litchy WJ, Minnerath S, et al. Hereditary motor and sensory neuropathywith diaphragm and vocal cord paresis. Ann Neurol. 1994;35:608-15.

  73. De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain. 1999;122:281-290.

  74. Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology. Dec 1993;43(12):2558-64. [Medline].

  75. Mastaglia FL, Nowak KJ, Stell R, Phillips BA, Edmondston JE, Dorosz SM, et al. Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry. Aug 1999;67(2):174-9. [Medline].

  76. De Jonghe P, Mersivanova I, Nelis E, Del Favero J, Martin JJ, Van Broeckhoven C, et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol. Feb 2001;49(2):245-9. [Medline].

  77. Senderek J, Bergmann C, Ramaekers VT, Nelis E, Bernert G, Makowski A. Mutations in the ganglioside-induced differentiation-associated protein-1 (GDAP1) gene in intermediate type autosomal recessive Charcot-Marie-Tooth neuropathy. Brain. Mar 2003;126(Pt 3):642-9. [Medline].

  78. Jordanova A, Irobi J, Thomas FP, Van Dijck P, Meerschaert K, Dewil M. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet. Feb 2006;38(2):197-202. [Medline].

  79. Bennett CL, Lawson VH, Brickell KL, Isaacs K, Seltzer W, Lipe HP. Late-onset hereditary axonal neuropathies. Neurology. Jul 1 2008;71(1):14-20. [Medline].

  80. Liao JP, Waclawik AJ. Nerve root hypertrophy in CMT type 1A. Neurology. Mar 9 2004;62(5):783. [Medline].

  81. Martinoli C, Schenone A, Bianchi S, Mandich P, Caponetto C, Abbruzzese M. Sonography of the median nerve in Charcot-Marie-Tooth disease. AJR Am J Roentgenol. Jun 2002;178(6):1553-6. [Medline].

  82. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. II. Neurologic, genetic, and electrophysiologic findings in various neuronal degenerations. Arch Neurol. Jun 1968;18(6):619-25. [Medline].

  83. Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology. Jun 1982;32(6):592-6. [Medline].

  84. Kaku DA, Parry GJ, Malamut R, Lupski JR, Garcia CA. Uniform slowing of conduction velocities in Charcot-Marie-Tooth polyneuropathy type 1. Neurology. Dec 1993;43(12):2664-7. [Medline].

  85. Gabreëls-Festen A, Wetering RV. Human nerve pathology caused by different mutational mechanisms of the PMP22 gene. Ann N Y Acad Sci. Sep 14 1999;883:336-43. [Medline].

  86. Behse F, Buchthal F. Peroneal muscular atrophy (PMA) and related disorders. II. Histological findings in sural nerves. Brain. Mar 1977;100 Pt 1:67-85. [Medline].

  87. Donaghy M, Sisodiya SM, Kennett R, McDonald B, Haites N, Bell C. Steroid responsive polyneuropathy in a family with a novel myelin protein zero mutation. J Neurol Neurosurg Psychiatry. Dec 2000;69(6):799-805. [Medline].

  88. Watanabe M, Yamamoto N, Ohkoshi N, Nagata H, Kohno Y, Hayashi A. Corticosteroid- responsive asymmetric neuropathy with a myelin protein zero gene mutation. Neurology. Sep 10 2002;59(5):767-9. [Medline].

  89. Ginsberg L, Malik O, Kenton AR, Sharp D, Muddle JR, Davis MB. Coexistent hereditary and inflammatory neuropathy. Brain. Jan 2004;127(Pt 1):193-202. [Medline].

  90. Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, Fontés M. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord. Mar 2007;17(3):248-53. [Medline].

  91. Pareyson D, Schenone A, Fabrizi GM, Santoro L, Padua L, Quattrone A. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. Pharmacol Res. Dec 2006;54(6):436-41. [Medline].

  92. Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. Apr 2011;10(4):320-328. [Medline].

  93. Meyer zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol. Jan 2007;61(1):61-72. [Medline].

  94. Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology. Jan 29 2008;70(5):378-83. [Medline].

  95. Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci. Mar 15 2006;242(1-2):47-54. [Medline].

  96. Antognini JF. Anaesthesia for Charcot-Marie-Tooth disease: a review of 86 cases. Can J Anaesth. Apr 1992;39(4):398-400. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.